Lung Cancer Screening and Prevention Act of 2025
Summary
HR1406 (Lung Cancer Screening and Prevention Act of 2025) would expand Medicare coverage to FDA-approved lung cancer screening tests beyond the current USPSTF-recommended set. The bill is in early committee stage with no authorized funding, limiting near-term market impact. GEHC, LH, and DGX are structural beneficiaries if passed, but passage is uncertain and distant.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1406 is early-stage legislation with no funding authorized and no legislative progress in 14 months
- 2.Passage would structurally benefit GEHC (imaging equipment), LH and DGX (clinical lab testing) through increased Medicare screening volumes
- 3.Near-term market impact is negligible; the bill faces an uncertain path through two House committees and both chambers
Market Implications
No near-term market implications from this bill given its stalled committee status. However, investors should monitor GEHC, LH, and DGX for structural upside if the bill gains momentum. GEHC's recent 15.72% monthly decline to $59.99 (near its 52-week low of $58.75) is unrelated to this legislation and may present a risk/reward consideration for exposure to diagnostic imaging, but the bill itself does not justify action today. LH at $260.32 and DGX at $192.87 have been relatively stable over the same period.
Full Analysis
- What happened: Representative Buchanan (R-FL) introduced HR1406 on February 18, 2025. The bill was referred to the Committee on Energy and Commerce and the Committee on Ways and Means. It has 8 cosponsors and remains in early committee stage as of April 30, 2026 — over 14 months with no further action. 2) The money trail: This is an authorization bill with NO authorized funding amount. It directs CMS to expand Medicare coverage but does not appropriate any funds. Actual spending would depend on Medicare reimbursement rates set by CMS through the national coverage determination process, and would flow through existing Medicare Part B payment mechanisms. 3) Structural winners: GEHC (diagnostic imaging equipment), LH and DGX (clinical lab testing services) would benefit from increased screening volumes if the bill becomes law. No direct losers. 4) Real market data analysis: GEHC has declined sharply — 12.84% in 7 days and 15.72% in 30 days, closing at $59.99 on April 30, near its 52-week low of $58.75. LH declined 1.32% in 7 days and 2.43% in 30 days, closing at $260.32. DGX declined 1.73% in 7 days and 1.59% in 30 days, closing at $192.87. Recent selling pressure on GEHC is severe and unrelated to this bill, which has been stalled for over a year. 5) Timeline: The bill must pass both House committees, receive a floor vote in the House, pass the Senate, and be signed by the President. With no action since referral in February 2025, legislative momentum is near zero in the current Congress session.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Regulatory expansion of Medicare coverage to FDA-approved lung cancer screening tests beyond current USPSTF recommendations, via CMS national coverage determination process
Who must act
Centers for Medicare & Medicaid Services (CMS)
What happens
CMS must set coverage and payment limits for additional lung cancer screening tests; screening volumes for diagnostic imaging and lab testing increase as Medicare beneficiaries gain access to a broader set of FDA-cleared tests
Stock impact
GEHC's diagnostic imaging segment (CT, PET, digital X-ray) supplies equipment used in lung cancer screening; increased screening volumes drive demand for imaging hardware, service contracts, and consumables. Imaging equipment is GEHC's primary revenue segment.
What the bill does
Regulatory expansion of Medicare coverage to FDA-approved lung cancer screening tests beyond current USPSTF recommendations, via CMS national coverage determination process
Who must act
Centers for Medicare & Medicaid Services (CMS)
What happens
CMS must set coverage and payment limits for additional lung cancer screening tests; screening volumes for diagnostic imaging and lab testing increase as Medicare beneficiaries gain access to a broader set of FDA-cleared tests
Stock impact
Labcorp's diagnostic testing services include lab-based lung cancer screening tests; increased Medicare-covered screening volumes boost testing revenue. Labcorp operates one of the two largest US clinical lab networks alongside DGX.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Find It Early Act
SUPPORT for Patients and Communities Reauthorization Act of 2025
ASAP Act
CHOICE for Veterans Act of 2025
Reducing Hereditary Cancer Act
Access to Breast Cancer Diagnosis Act of 2025
Increasing Access to Lung Cancer Screening Act
Supporting Healthy Moms and Babies Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →